Literature DB >> 21289600

Influence of cocaine history on the behavioral effects of Dopamine D(3) receptor-selective compounds in monkeys.

B L Blaylock1, R W Gould, A Banala, P Grundt, R R Luedtke, A H Newman, M A Nader.   

Abstract

Although dopamine D(3) receptors have been associated with cocaine abuse, little is known about the consequences of chronic cocaine on functional activity of D(3) receptor-preferring compounds. This study examined the behavioral effects of D(3) receptor-selective 4-phenylpiperazines with differing in vitro functional profiles in adult male rhesus monkeys with a history of cocaine self-administration and controls. In vitro assays found that PG 619 (N-(3-hydroxy-4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide HCl) was a potent D(3) antagonist in the mitogenesis assay, but a fully efficacious agonist in the adenylyl cyclase assay, NGB 2904 (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide HCl) was a selective D(3) antagonist, whereas CJB 090 (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide HCl) exhibited a partial agonist profile in both in vitro assays. In behavioral studies, the D(3) preferential agonist quinpirole (0.03-1.0 mg/kg, i.v.) dose-dependently elicited yawns in both groups of monkeys. PG 619 and CJB 090 elicited yawns only in monkeys with an extensive history of cocaine, whereas NGB 2904 did not elicit yawns, but did antagonize quinpirole and PG 619-elicited yawning in cocaine-history monkeys. In another experiment, doses of PG 619 that elicited yawns did not alter response rates in monkeys self-administering cocaine (0.03-0.3 mg/kg per injection). Following saline extinction, cocaine (0.1 mg/kg) and quinpirole (0.1 mg/kg), but not PG 619 (0.1 mg/kg), reinstated cocaine-seeking behavior. When given before a cocaine prime, PG 619 decreased cocaine-elicited reinstatement. These findings suggest that (1) an incongruence between in vitro and in vivo assays, and (2) a history of cocaine self-administration can affect in vivo efficacy of D(3) receptor-preferring compounds PG 619 and CJB 090, which appear to be dependent on the behavioral assay.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289600      PMCID: PMC3070922          DOI: 10.1038/npp.2010.248

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  50 in total

1.  Effects of dopamine D(1-like) and D(2-like) agonists on cocaine self-administration in rhesus monkeys: rapid assessment of cocaine dose-effect functions.

Authors:  S B Caine; S S Negus; N K Mello
Journal:  Psychopharmacology (Berl)       Date:  2000-01       Impact factor: 4.530

Review 2.  Drug efficacy at G protein-coupled receptors.

Authors:  Terry Kenakin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

3.  Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys.

Authors:  Jennifer L Martelle; Renee Claytor; Jason T Ross; Beth A Reboussin; Amy Hauck Newman; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2007-02-01       Impact factor: 4.030

4.  The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats.

Authors:  Zheng-Xiong Xi; Amy Hauck Newman; Jeremy G Gilbert; Arlene C Pak; Xiao-Qing Peng; Charles R Ashby; Leah Gitajn; Eliot L Gardner
Journal:  Neuropsychopharmacology       Date:  2005-10-05       Impact factor: 7.853

5.  Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.

Authors:  Gregory T Collins; Jeffrey M Witkin; Amy H Newman; Kjell A Svensson; Peter Grundt; Jianjing Cao; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-04-15       Impact factor: 4.030

6.  Yawning produced by dopamine agonists in rhesus monkeys.

Authors:  R A Code; A H Tang
Journal:  Eur J Pharmacol       Date:  1991-08-29       Impact factor: 4.432

7.  PET imaging of dopamine D2 receptor and transporter availability during acquisition of cocaine self-administration in rhesus monkeys.

Authors:  Paul W Czoty; H Donald Gage; Susan H Nader; Beth A Reboussin; Michael Bounds; Michael A Nader
Journal:  J Addict Med       Date:  2007-03       Impact factor: 3.702

8.  Cocaine-seeking behavior in response to drug-associated stimuli in rats: involvement of D3 and D2 dopamine receptors.

Authors:  L Cervo; F Carnovali; J A Stark; T Mennini
Journal:  Neuropsychopharmacology       Date:  2003-04-02       Impact factor: 7.853

Review 9.  Medication development for addictive disorders: the state of the science.

Authors:  Frank J Vocci; Jane Acri; Ahmed Elkashef
Journal:  Am J Psychiatry       Date:  2005-08       Impact factor: 18.112

10.  The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys.

Authors:  Cindy Achat-Mendes; Donna M Platt; Amy H Newman; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2009-06-10       Impact factor: 4.530

View more
  17 in total

1.  Dopamine D3 receptor function and cocaine exposure.

Authors:  Brandi L Blaylock; Michael A Nader
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

2.  Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55.

Authors:  Timothy H C Cheung; Amy L Loriaux; Suzanne M Weber; Kayla N Chandler; Jeffrey D Lenz; Romina F Schaan; Robert H Mach; Robert R Luedtke; Janet L Neisewander
Journal:  J Pharmacol Exp Ther       Date:  2013-09-09       Impact factor: 4.030

Review 3.  Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction.

Authors:  Bernard Le Foll; Patricia Di Ciano
Journal:  Eur Neuropsychopharmacol       Date:  2014-09-16       Impact factor: 4.600

4.  Further characterization of quinpirole-elicited yawning as a model of dopamine D3 receptor activation in male and female monkeys.

Authors:  Susan E Martelle; Susan H Nader; Paul W Czoty; William S John; Angela N Duke; Pradeep K Garg; Sudha Garg; Amy H Newman; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2014-05-29       Impact factor: 4.030

Review 5.  Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.

Authors:  Thomas M Keck; Caitlin Burzynski; Lei Shi; Amy Hauck Newman
Journal:  Adv Pharmacol       Date:  2014

Review 6.  PET studies in nonhuman primate models of cocaine abuse: translational research related to vulnerability and neuroadaptations.

Authors:  Robert W Gould; Angela N Duke; Michael A Nader
Journal:  Neuropharmacology       Date:  2013-02-28       Impact factor: 5.250

7.  Phenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in rats.

Authors:  T H C Cheung; B C Nolan; L R Hammerslag; S M Weber; J P Durbin; N A Peartree; R H Mach; R R Luedtke; J L Neisewander
Journal:  Neuropharmacology       Date:  2012-08-31       Impact factor: 5.250

8.  Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history.

Authors:  Robert W Gould; Pradeep K Garg; Sudha Garg; Michael A Nader
Journal:  Neuropharmacology       Date:  2012-08-23       Impact factor: 5.250

9.  2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.

Authors:  Amy Hauck Newman; Francisco O Battiti; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-09-24       Impact factor: 7.446

10.  Eating high fat chow and the behavioral effects of direct-acting and indirect-acting dopamine receptor agonists in female rats.

Authors:  Katherine M Serafine; Todd A Bentley; Amandine E Grenier; Charles P France
Journal:  Behav Pharmacol       Date:  2014-08       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.